| scholarly article | Q13442814 |
| P50 | author | Carine Tran-Perennou | Q41608395 |
| Brigitte Sigal-Zafrani | Q41608497 | ||
| Olivier Delattre | Q30119391 | ||
| Nathalie Auger | Q40756210 | ||
| Anne Vincent-Salomon | Q41605826 | ||
| Xavier Sastre-Garau | Q41607337 | ||
| Patricia de Cremoux | Q41607986 | ||
| P2093 | author name string | Franck Assayag | |
| Marie-France Poupon | |||
| Elisabetta Marangoni | |||
| Véronique Diéras | |||
| Ludmilla de Plater | |||
| Gonzague De Pinieux | |||
| Charlotte Guyader | |||
| Jean-Gabriel Judde | |||
| Armelle Degeorges | |||
| Magali Rebucci | |||
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| xenograft | Q64148587 | ||
| breast cancer | Q128581 | ||
| P304 | page(s) | 3989-3998 | |
| P577 | publication date | 2007-07-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | A new model of patient tumor-derived breast cancer xenografts for preclinical assays | |
| P478 | volume | 13 |
| Q34122934 | "A novel in vivo model for the study of human breast cancer metastasis using primary breast tumor-initiating cells from patient biopsies". |
| Q28598343 | A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds |
| Q47577143 | A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors |
| Q58094727 | A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation |
| Q39391009 | A deuterated analog of dasatinib disrupts cell cycle progression and displays anti-non-small cell lung cancer activity in vitro and in vivo |
| Q39392736 | A patient-derived xenograft mouse model generated from primary cultured cells recapitulates patient tumors phenotypically and genetically. |
| Q28480588 | A phenotypic mouse model of basaloid breast tumors |
| Q37067545 | A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models |
| Q38314870 | A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations |
| Q58771181 | A subset of esophageal squamous cell carcinoma patient-derived xenografts respond to cetuximab, which is predicted by high EGFR expression and amplification |
| Q37240838 | A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy |
| Q35760892 | Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes |
| Q36750699 | Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer |
| Q35953315 | Aminopeptidase P Mediated Targeting for Breast Tissue Specific Conjugate Delivery. |
| Q26772895 | An Integrative Approach to Precision Cancer Medicine Using Patient-Derived Xenografts |
| Q38789039 | Anti-Tumoral Effects of Anti-Progestins in a Patient-Derived Breast Cancer Xenograft Model |
| Q90405381 | Anti-oral cancer effects of triptolide by downregulation of DcR3 in vitro, in vivo, and in preclinical patient-derived tumor xenograft model |
| Q92620214 | Application of Highly Immunocompromised Mice for the Establishment of Patient-Derived Xenograft (PDX) Models |
| Q28545204 | Appropriateness of using patient-derived xenograft models for pharmacologic evaluation of novel therapies for esophageal/gastro-esophageal junction cancers |
| Q37690969 | Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation |
| Q37715399 | Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer |
| Q51441965 | B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy. |
| Q36123789 | Biobanking of patient and patient-derived xenograft ovarian tumour tissue: efficient preservation with low and high fetal calf serum based methods |
| Q26770495 | Bioengineering Models for Breast Cancer Research |
| Q37605221 | Biopathological Significance of TLR9 Expression in Cancer Cells and Tumor Microenvironment Across Invasive Breast Carcinomas Subtypes. |
| Q92757507 | Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations |
| Q41135046 | Breast tumor PDXs are genetically plastic and correspond to a subset of aggressive cancers prone to relapse |
| Q49619782 | Bridging the divide: preclinical research discrepancies between triple-negative breast cancer cell lines and patient tumors |
| Q37141981 | CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts. |
| Q37685449 | CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients |
| Q38764251 | Catalog of genetic progression of human cancers: breast cancer |
| Q28552410 | Characterization of Breast Cancer Preclinical Models Reveals a Specific Pattern of Macrophage Polarization |
| Q58694894 | Characterization of drug responses of mini patient-derived xenografts in mice for predicting cancer patient clinical therapeutic response |
| Q35732707 | Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies |
| Q39787293 | Characterization of patient-derived tumor xenografts (PDXs) as models for estrogen receptor positive (ER+HER2- and ER+HER2+) breast cancers |
| Q96432078 | Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumors |
| Q37075234 | Chromatin Regulators as a Guide for Cancer Treatment Choice |
| Q90620231 | Clinical Implementation of Precision Medicine in Gastric Cancer |
| Q38704826 | Clinical value of R-spondins in triple-negative and metaplastic breast cancers |
| Q37709099 | Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer. |
| Q89842731 | Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers |
| Q37093269 | Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models |
| Q89457550 | Comedications influence immune infiltration and pathological response to neoadjuvant chemotherapy in breast cancer |
| Q48569329 | Comparison of Clinical Features and Outcomes in Epithelial Ovarian Cancer according to Tumorigenicity in Patient-Derived Xenograft Models. |
| Q38765553 | Comprehensive characterization of the patient-derived xenograft and the paralleled primary hepatocellular carcinoma cell line |
| Q36140720 | Correlation between tumor engraftment in patient-derived xenograft models and clinical outcomes in colorectal cancer patients |
| Q38689944 | Current Update of Patient-Derived Xenograft Model for Translational Breast Cancer Research |
| Q33667686 | Current status and perspectives of patient-derived xenograft models in cancer research |
| Q38747834 | Cytidine Deaminase Deficiency Reveals New Therapeutic Opportunities against Cancer |
| Q21131727 | Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy |
| Q92879104 | Development of Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and Chemotherapy-Resistant Breast Cancer PDXs |
| Q34566212 | Differential in vivo tumorigenicity of distinct subpopulations from a luminal-like breast cancer xenograft |
| Q42497866 | Dynamic 2-Deoxy-2-[18F]Fluoro-D-Glucose Positron Emission Tomography for Chemotherapy Response Monitoring of Breast Cancer Xenografts |
| Q24621116 | Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts |
| Q90359795 | Engineered Fibrillar Fibronectin Networks as Three-Dimensional Tissue Scaffolds |
| Q38908688 | Enhanced serum proteolysis resistance of cell-penetrating peptides |
| Q47137308 | Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study |
| Q89551742 | Establishment and Characterisation by Expression Microarray of Patient-Derived Xenograft Panel of Human Pancreatic Adenocarcinoma Patients |
| Q34256029 | Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation |
| Q36633405 | Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer. |
| Q51512708 | Establishment and characterization of esophageal squamous cell carcinoma patient-derived xenograft mouse models for preclinical drug discovery. |
| Q42722068 | Establishment and characterization of patient tumor-derived head and neck squamous cell carcinoma xenografts |
| Q35119526 | Establishment and characterization of patient-derived tumor xenograft using gastroscopic biopsies in gastric cancer |
| Q91949994 | Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer |
| Q53418683 | Establishment of a murine breast tumor model by subcutaneous or orthotopic implantation. |
| Q35921330 | Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation |
| Q33827461 | Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis |
| Q64950925 | Establishment of pancreatic cancer patient-derived xenograft models and comparison of the differences among the generations. |
| Q41158938 | Establishment of patient derived xenografts as functional testing of lung cancer aggressiveness. |
| Q35798580 | Establishment of patient-derived cancer xenografts in immunodeficient NOG mice |
| Q36307708 | Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways |
| Q28484668 | Establishment, characterization and chemosensitivity of three mismatch repair deficient cell lines from sporadic and inherited colorectal carcinomas |
| Q36488310 | Evaluation of PET Imaging Performance of the TSPO Radioligand [18F]DPA-714 in Mouse and Rat Models of Cancer and Inflammation |
| Q56889140 | Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models |
| Q36198223 | Evaluation of anti-tumorigenic activity of BP3B against colon cancer with patient-derived tumor xenograft model |
| Q100295114 | Evaluation of the treatment strategies on patient-derived xenograft mice of human breast tumor |
| Q48500250 | Examining the utility of patient-derived xenograft mouse models |
| Q64108509 | Factors that influence response classifications in chemotherapy treated patient-derived xenografts (PDX) |
| Q47283164 | First-In-Human Phase 1 CRISPR Gene Editing Cancer Trials: Are We Ready? |
| Q28079323 | Genetically engineered mouse models in oncology research and cancer medicine |
| Q90712068 | Genomic evolution of cancer models: perils and opportunities |
| Q53669221 | HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts. |
| Q41950745 | High-risk gastrointestinal stromal tumour (GIST) and synovial sarcoma display similar angiogenic profiles: a nude mice xenograft study |
| Q92451925 | High-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancer |
| Q21134541 | Histological and molecular evaluation of patient-derived colorectal cancer explants |
| Q34897367 | Human breast cancer and lymph node metastases express Gb3 and can be targeted by STxB-vectorized chemotherapeutic compounds. |
| Q92377049 | Identification of Novel Anti-Liver Cancer Small Molecules with Better Therapeutic Index than Sorafenib via Zebrafish Drug Screening Platform |
| Q89454919 | Identification of synergistic drug combinations using breast cancer patient-derived xenografts |
| Q50113746 | Imaging-guided photo-therapeutic nanoporphyrin synergized HSP90 inhibitor in patient-derived xenograft bladder cancer model |
| Q39850341 | Immunodeficient mouse strains display marked variability in growth of human melanoma lung metastases |
| Q28545022 | In search of the molecular mechanisms mediating the inhibitory effect of the GnRH antagonist degarelix on human prostate cell growth |
| Q33588117 | In vivo models in breast cancer research: progress, challenges and future directions |
| Q30372076 | In vivo photoacoustic tomography of EGFR overexpressed in hepatocellular carcinoma mouse xenograft. |
| Q35852989 | Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triple-negative breast cancers |
| Q90430590 | Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition |
| Q35587164 | Initiation and characterization of small cell lung cancer patient-derived xenografts from ultrasound-guided transbronchial needle aspirates |
| Q64957213 | Integrative In Vivo Drug Testing Using Gene Expression Signature and Patient-Derived Xenografts from Treatment-Refractory HER2 Positive and Triple-Negative Subtypes of Breast Cancer. |
| Q37689772 | Interplay of choline metabolites and genes in patient-derived breast cancer xenografts |
| Q39095733 | Interrogating open issues in cancer precision medicine with patient-derived xenografts. |
| Q37580013 | Labeling of Breast Cancer Patient-derived Xenografts with Traceable Reporters for Tumor Growth and Metastasis Studies. |
| Q38213543 | Lessons learned from the intrinsic subtypes of breast cancer in the quest for precision therapy |
| Q92978419 | Lipoic acid decreases breast cancer cell proliferation by inhibiting IGF-1R via furin downregulation |
| Q35059856 | Lobular breast cancer: molecular basis, mouse and cellular models |
| Q28512158 | Loss of p53 partially rescues embryonic development of Palb2 knockout mice but does not foster haploinsufficiency of Palb2 in tumour suppression |
| Q38255064 | Mechanism-based cancer therapy: resistance to therapy, therapy for resistance |
| Q40665907 | Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer |
| Q33779673 | Melatonin exerts anti-oral cancer effect via suppressing LSD1 in patient-derived tumor xenograft models |
| Q30437720 | Metastasis Research Society-American Association For Cancer Research Joint Conference on Metastasis. |
| Q38207530 | Mimicking breast cancer-induced bone metastasis in vivo: current transplantation models and advanced humanized strategies |
| Q37708733 | Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts. |
| Q33641924 | Modeling platinum sensitive and resistant high-grade serous ovarian cancer: development and applications of experimental systems |
| Q41128277 | Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models |
| Q21195204 | Molecular profiling of patient-derived breast cancer xenografts |
| Q58776633 | Mouse models in the era of large human tumour sequencing studies |
| Q60924105 | Mouse models of breast cancer in preclinical research |
| Q34503914 | Multimodal In Vivo Imaging of Tumorigenesis and Response to Chemotherapy in a Transgenic Mouse Model of Mammary Cancer |
| Q38931192 | Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction |
| Q38793074 | NSCLC harboring EGFR exon-20 insertions after the regulatory C-helix of kinase domain responds poorly to known EGFR inhibitors |
| Q92724375 | Oestrogen Non-Genomic Signalling is Activated in Tamoxifen-Resistant Breast Cancer |
| Q39185528 | Optimization of tumor xenograft dissociation for the profiling of cell surface markers and nutrient transporters. |
| Q59209822 | Optimizing the design of population-based patient-derived tumor xenograft studies to better predict clinical response |
| Q36414048 | Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structure |
| Q42716087 | Overcoming erlotinib resistance with tailored treatment regimen in patient-derived xenografts from naïve Asian NSCLC patients |
| Q54978311 | PKD1 is a potential biomarker and therapeutic target in triple-negative breast cancer. |
| Q92941564 | Patient-Derived Xenograft Models of Breast Cancer and Their Application |
| Q53194722 | Patient-Derived Xenografts of Breast Cancer. |
| Q37507350 | Patient-derived Mammosphere and Xenograft Tumour Initiation Correlates with Progression to Metastasis |
| Q36903447 | Patient-derived breast tumor xenografts facilitating personalized cancer therapy |
| Q34125001 | Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review |
| Q37281532 | Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures |
| Q24627425 | Patient-derived tumor xenografts: transforming clinical samples into mouse models |
| Q24604068 | Patient-derived tumour xenografts as models for oncology drug development |
| Q28080046 | Patient-derived tumour xenografts for breast cancer drug discovery |
| Q39057246 | Patient-derived xenograft (PDX) models in basic and translational breast cancer research. |
| Q36946697 | Patient-derived xenograft (PDX) tumors increase growth rate with time. |
| Q27026531 | Patient-derived xenograft models of breast cancer and their predictive power |
| Q26741651 | Patient-derived xenograft models of colorectal cancer in pre-clinical research: a systematic review |
| Q92741011 | Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance |
| Q26829125 | Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment |
| Q34205518 | Patient-derived xenograft models: an emerging platform for translational cancer research |
| Q38732336 | Patient-derived xenografts as tools in pharmaceutical development |
| Q45068320 | Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors |
| Q35884941 | Patient-derived xenografts of non small cell lung cancer: resurgence of an old model for investigation of modern concepts of tailored therapy and cancer stem cells |
| Q33739184 | Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition |
| Q38317188 | Patient-derived xenografts recapitulate molecular features of human uveal melanomas |
| Q28067191 | Patient-derived xenografts: a relevant preclinical model for drug development |
| Q35663687 | Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies |
| Q42505998 | Pentraxin-3 is a PI3K signaling target that promotes stem cell-like traits in basal-like breast cancers. |
| Q35832158 | Pharmacological inhibition of p38 MAPK reduces tumor growth in patient-derived xenografts from colon tumors |
| Q42462047 | Positron emission tomography and pharmacokinetics of 2-[18F]-fluoroethyl choline for metabolic studies in breast cancer xenografts |
| Q84466734 | Preclinical xenograft models of human sarcoma show nonrandom loss of aberrations |
| Q34465302 | Predictive gene signature of response to the anti-TweakR mAb PDL192 in patient-derived breast cancer xenografts |
| Q44944972 | Primary esophageal and gastro-esophageal junction cancer xenograft models: clinicopathological features and engraftment |
| Q28083993 | Prioritizing therapeutic targets using patient-derived xenograft models |
| Q38421751 | Prognostic and functional importance of the engraftment-associated genes in the patient-derived xenograft models of triple-negative breast cancers |
| Q64947844 | Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers. |
| Q93161800 | Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state |
| Q30366115 | Reversible p53 inhibition prevents cisplatin ototoxicity without blocking chemotherapeutic efficacy |
| Q31081891 | Risk of hormone escape in a human prostate cancer model depends on therapy modalities and can be reduced by tyrosine kinase inhibitors |
| Q33739307 | Selective gene-expression profiling of migratory tumor cells in vivo predicts clinical outcome in breast cancer patients |
| Q35779325 | Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737 |
| Q51253404 | Shear wave elastography of tumour growth in a human breast cancer model with pathological correlation. |
| Q34700019 | Specific targeting of caspase-9/PP2A interaction as potential new anti-cancer therapy |
| Q33898564 | Stability of preclinical models of aggressive renal cell carcinomas |
| Q38735015 | Steroid Hormone Receptor Positive Breast Cancer Patient-Derived Xenografts |
| Q37844487 | Studying therapy response and resistance in mouse models for BRCA1-deficient breast cancer |
| Q92727723 | Synthetic miR-143 Exhibited an Anti-Cancer Effect via the Downregulation of K-RAS Networks of Renal Cell Cancer Cells In Vitro and In Vivo |
| Q34735167 | TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer |
| Q37565435 | Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers. |
| Q37775105 | Targeting tumour-initiating cells to improve the cure rates for triple-negative breast cancer. |
| Q91715241 | The Detection and Morphological Analysis of Circulating Tumor and Host Cells in Breast Cancer Xenograft Models |
| Q49284173 | The Generation and Application of Patient-Derived Xenograft Model for Cancer Research |
| Q38694934 | The Phosphatidylinositol 3-kinase Pathway as a Potential Therapeutic Target in Bladder Cancer. |
| Q91259737 | The arginine methyltransferase PRMT1 regulates IGF-1 signaling in breast cancer |
| Q40539652 | The combinational therapy of trastuzumab and cetuximab inhibits tumor growth in a patient-derived tumor xenograft model of gastric cancer |
| Q35049084 | The contributions of HIF-target genes to tumor growth in RCC. |
| Q35227197 | The extent of inflammatory infiltration in primary cancer tissues is associated with lymphomagenesis in immunodeficient mice |
| Q38726672 | The molecular mechanisms underlying the ERα-36-mediated signaling in breast cancer |
| Q34291977 | The need for complex 3D culture models to unravel novel pathways and identify accurate biomarkers in breast cancer |
| Q36321878 | The sialyl-glycolipid stage-specific embryonic antigen 4 marks a subpopulation of chemotherapy-resistant breast cancer cells with mesenchymal features |
| Q47401744 | Three-Dimensional Tissue Models and Available Probes for Multi-Parametric Live Cell Microscopy: A Brief Overview. |
| Q47140067 | Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3. |
| Q28541502 | Translational validation of personalized treatment strategy based on genetic characteristics of glioblastoma |
| Q36361515 | Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models |
| Q45865848 | Treatment of patient tumor-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus |
| Q35534811 | Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. |
| Q24630783 | Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes |
| Q53034307 | Ultrahigh dose-rate FLASH irradiation increases the differential response between normal and tumor tissue in mice. |
| Q27853297 | Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers. |
| Q47385711 | When Enough Is Enough: Decision Criteria for Moving a Known Drug into Clinical Testing for a New Indication in the Absence of Preclinical Efficacy Data |
| Q37416460 | Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors |
| Q33757112 | microRNA-148a dysregulation discriminates poor prognosis of hepatocellular carcinoma in association with USP4 overexpression. |
| Q58615653 | pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry |
Search more.